[Long-term outcomes of prostate cancer patients with lymph nodes metastasis after radical prostatectomy and pelvic lymph node dissection].

Autor:	De Vergie S; Service d'urologie, CHU de Nantes, 1, place Alexis-Ricordeau, 44000 Nantes, France. Electronic address: stephanedervergie@yahoo.fr., Gaschignard N; Service d'urologie, centre hospitalier de la Roche/Yon, 85000 La Roche/Yon, France., Baron M; Service d'urologie, centre hospitalier de Saint-Nazaire, 44600 Saint-Nazaire, France., Branchereau J; Service d'urologie, CHU de Nantes, 1, place Alexis-Ricordeau, 44000 Nantes, France., Luyckx F; Service d'urologie, centre hospitalier de la Roche/Yon, 85000 La Roche/Yon, France., Butel T; Service d'oncologie pédiatrique, institut Gustave-Roussy, 94805 Villejuif, France., Perrouin-Verbe MA; Service d'urologie, CHU de Nantes, 1, place Alexis-Ricordeau, 44000 Nantes, France., Bouchot O; Service d'urologie, CHU de Nantes, 1, place Alexis-Ricordeau, 44000 Nantes, France., Rigaud J; Service d'urologie, CHU de Nantes, 1, place Alexis-Ricordeau, 44000 Nantes, France. Electronic address: jrigaud@chu-nantes.fr.
Jazyk:	francouzština
Zdroj:	Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie [Prog Urol] 2018 Jan; Vol. 28 (1), pp. 25-31. Date of Electronic Publication: 2017 Dec 06.
DOI:	10.1016/j.purol.2017.10.003
Abstrakt:	Introduction: The aim of this study was to evaluate biochemical recurrence-free survival (RFS) and to identify useful predictors of such survival in localized prostate cancer patients (cN0) and pelvic lymph node metastasis (pN+) treated with radical prostatectomy and pelvic lymph node dissection. Patients and Methods: This multicenter and retrospective study, assessed overall survival (OS), cancer specific survival (CSS) and biochemical recurrence-free survival (RFS), between January 2005 until December 2010 with 5 years of distance. We evaluated factors predicting long-term RFS in node positive prostate cancer patients. Results: Thus, 30 patients were included. Median follow-up was 89.9±27.4 months. After surgery, patients were treated with surveillance (n=4, 13.5%), adjuvant hormone therapy (n=22, 73%) or combination of radio and hormone therapy, (n=4, 13.5%). During the follow-up, 50% of patients had biochemical recurrence, with a mean time period of 38±30 months. Five and 10-year RFS were 57% and 41% respectively. Extra lymph nodes extension (P=0.00021) and pathological margin status (P=0.0065) were independent predictors of 5-year RFS. Conclusion: Biochemical RFS of patients treated with radical prostatectomy and subclinical lymph node metastatic disease is adequate and multifactorial. However, this study identifies pathological margin status and extra lymph node extension as independent factors of b RFS. Level of Evidence: 4. (Copyright © 2017 Elsevier Masson SAS. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu